Introduction:

Osteoarthritis is a type of arthritis that occurs when flexible tissue at the ends of bones wears down. Osteoarthritis is a degenerative disease that often results in chronic pain and worsens over time. Cartilage loss in a joint causes the joint disease osteoarthritis. The stages of osteoarthritis of the knee ranging from normal, minor, mild, moderate and severe stages. The treatment includes changes in lifestyle, diet plans, over-the-counter medications like NSAIDs and Acetaminophen, physical therapy, occupational therapy, and surgery.

The global Osteoarthritis Therapeutics market size was estimated to be at USD XXX million in 2019, and is expected to grow at a CAGR of XX% during forecast period to reach USD XXX million in 2027.

Market Dynamics:

The improving healthcare facilities and presence of most vulnerable population in developing countries is most likely to fuel the growth of the global osteoarthritis therapeutics market. Increasing research and development activities for novel treatment is also expected to result in introduction of new products and hence anticipated to drive the growth of the market during forecast period. On the flip side, the high cost associated with branded products and side effects resulting adverse events are expected to limit the growth of the market during forecast period. Moreover, the companies that are focusing on developing personalized medicines are presenting huge opportunities for themselves in this market.

COVID-19 Impact:

The impact of COVID-19 pandemic has resulted in the disruption of production as well as distribution network due to logistic issues. Moreover, the impact on patient visits and shift of regular medical care to COVID care have resulted in negative impact on the global osteoarthritis therapeutics market. The slight negative impact of COVID-19 pandemic has been observed on global osteoarthritis therapeutics market.

Global Osteoarthritis Therapeutics Market

Source: Precise Market Intelligence, 2020

Segmentation:

The market has been segmented based on form, indication, end user and region.

  • By Drugs
    • Nonsteroidal Anti-inflammatory Drugs
    • Corticosteroids
    • Analgesics
    • Viscosupplementation Agents
    • Others
       
  • By Disease Type
    • Hand Osteoarthritis
    • Knee Osteoarthritis
    • Hip Osteoarthritis
    • Small Joint Osteoarthritis
       
  • By Distribution Channels
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
       
  • By Region
    • North America (U.S., Canada)
    • Europe (U.K., France, Germany, Italy, Spain, and rest of Europe)
    • Asia Pacific (China, Japan, India, and Rest of Asia Pacific)
    • South America (Brazil, Mexico, and Rest of South America)
    • Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa)

Based on disease indication, the knee osteoarthritis segment is expected to remain dominant throughout the forecast period due to high incidence rate. Based on drugs, viscosupplementation agents segment accounted to highest market share. While, the hospital pharmacies segment dominated the end users, Europe has the largest market share among regions.

Osteoarthritis Therapeutics Market, By Region, 2019

Source: Precise Market Intelligence, 2020

Competition Landscape:

The prominent companies in the market are; Sanofi, Bayer AG, Zyla Life Sciences, Novartis AG, Pfizer Inc., Johnson & Johnson Services, Inc, Eli Lilly and Company, Merck & Co., Inc, ABIOGEN PHARMA S.p.A., Abbott, Ampio Pharmaceuticals Inc., and others.

For better understanding of revenue contribution of each technology to the Osteoarthritis Therapeutics Market, ask an expert analyst